NasdaqCM:VRDNBiotechs
A Look At Viridian Therapeutics (VRDN) Valuation After Positive REVEAL-1 Phase 3 Elegrobart Results
Viridian Therapeutics (VRDN) just reported positive topline Phase 3 REVEAL-1 data for elegrobart in active thyroid eye disease, with both dosing schedules meeting key proptosis and diplopia endpoints versus placebo.
See our latest analysis for Viridian Therapeutics.
Even with the encouraging REVEAL-1 topline readout, Viridian’s recent 7 day share price return of 33.19% and 30 day share price return of 35.74% show momentum has faded. However, the 1 year total shareholder return of 48.93% still...